Fate Therapeutics Inc
$ 1.51
3.42%
23 Feb - close price
- Market Cap 174,182,000 USD
- Current Price $ 1.51
- High / Low $ 1.54 / 1.40
- Stock P/E N/A
- Book Value 2.03
- EPS -1.33
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.52 %
- 52 Week High 1.94
- 52 Week Low 0.66
About
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is headquartered in San Diego, California.
Analyst Target Price
$4.94
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-12 | 2025-05-07 | 2025-02-24 | 2024-11-06 | 2024-08-13 | 2024-05-09 | 2024-02-26 | 2023-11-08 | 2023-08-08 | 2023-05-03 | 2023-02-28 |
| Reported EPS | -0.27 | -0.29 | -0.32 | -0.44 | -0.4 | -0.33 | -0.47 | -0.45 | -0.46 | -0.54 | -0.19 | -0.58 |
| Estimated EPS | -0.3 | -0.34 | -0.3794 | -0.4238 | -0.4122 | -0.48 | -0.49 | -0.52 | -0.57 | -0.59 | -0.62 | -0.86 |
| Surprise | 0.03 | 0.05 | 0.0594 | -0.0162 | 0.0122 | 0.15 | 0.02 | 0.07 | 0.11 | 0.05 | 0.43 | 0.28 |
| Surprise Percentage | 10% | 14.7059% | 15.6563% | -3.8226% | 2.9597% | 31.25% | 4.0816% | 13.4615% | 19.2982% | 8.4746% | 69.3548% | 32.5581% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.27 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FATE
2026-02-17 12:27:25
Kaskela Law LLC has initiated an investigation into Fate Therapeutics, Inc. (NASDAQ: FATE) on behalf of long-term investors following an amended securities fraud complaint. The complaint alleges that Fate made false statements regarding its collaboration with Janssen Pharmaceuticals, which was later terminated, causing Fate's stock to drop over 61% in one day. The firm is seeking to determine if Fate's board breached fiduciary duties and encourages affected shareholders to contact them.
2026-02-16 18:28:35
The report "IPSC-derived NK Cells Pipeline Insight 2026" from DelveInsight covers clinical developments in iPSC-derived NK cell therapies, highlighting over 12 companies and 15 pipeline drugs. Key players like Century Therapeutics and Fate Therapeutics are advancing treatments for autoimmune disorders, lymphomas, and other cancers. The report emphasizes the potential of iPSC-derived NK cells as a scalable, off-the-shelf option for next-generation cancer immunotherapies.
2026-02-10 16:57:52
Fate Therapeutics (NASDAQ:FATE) shares recently crossed above their 50-day moving average, trading at $1.12 with significant volume. The company, which develops cellular immunotherapies, slightly surpassed its quarterly earnings and revenue expectations but remains unprofitable. Analyst consensus on the stock is "Hold" with an average target price of $3.92, while institutional investors maintain a substantial ownership of 97.54%.
2026-02-04 05:27:47
Nine analysts have issued a consensus "Hold" rating for Fate Therapeutics, Inc. (NASDAQ:FATE), with an average 12-month price target of $3.92. The biopharmaceutical company's shares are trading at $1.19 with a market cap of $137.3 million, and it reported negative earnings with a P/E ratio of -0.90. Institutional investors hold approximately 97.54% of the stock.
2026-02-03 16:05:00
Fate Therapeutics, Inc. announced new employee inducement awards in accordance with Nasdaq Listing Rule 5635(c)(4). A newly-hired non-executive employee received non-qualified stock options for 120,000 shares and restricted stock units for 90,000 shares. These grants, approved by the Compensation Committee, are designed to vest over four years, contingent on continuous employment.
2026-02-03 16:05:00
Fate Therapeutics, Inc. (NASDAQ: FATE) announced that it granted inducement awards to a newly-hired non-executive employee on February 1, 2026. The awards include non-qualified stock options for 120,000 shares and restricted stock units (RSUs) representing 90,000 shares, as approved by the Compensation Committee. These grants are part of the Company's Amended and Restated Inducement Equity Plan and comply with Nasdaq Listing Rule 5635(c)(4).
